Corticosteroid News and Research

RSS

Corticosteroids are any steroid hormones made in the adrenal cortex (the outer part of the adrenal gland). They are also made in the laboratory. Corticosteroids have many different effects in the body, and are used to treat many different conditions. They may be used as hormone replacement, to suppress the immune system, and to treat some side effects of cancer and its treatment. Corticosteroids are also used to treat certain lymphomas and lymphoid leukemias.

Study shows 1 in 8 patients at risk of developing serious ADE take OTC NSAIDs

A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that one in eight patients at risk of developing a serious adverse drug event is taking over-the-counter non-steroidal anti-inflammatory drugs, often to treat a musculoskeletal complaint.

13 Jun 2013

$Epidural steroid injection is associated with increased spinal fracture$

Epidural steroid injection is associated with increased spinal fracture

Most aging adults will experience back pain or a spinal disorder at some time in their life. In fact, about 25.8 million visits were made to physicians' offices due to primary back problems. Treatment focuses on pain relief and is available in both non-surgical (medication or physical therapy) and surgical forms.

7 Jun 2013

Prosonix commences Phase 2 clinical study of PSX1002 for treatment of moderate to severe COPD

Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, has initiated a Phase 2 clinical study with PSX1002 that will assess its effect on lung function and the safety of a range of doses in patients with moderate to severe chronic obstructive pulmonary disease.

23 May 2013

A*STAR, Cytos Biotechnology provide update on Phase 1 clinical trial of H1N1 influenza vaccine

Singapore's Agency for Science, Technology and Research and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their H1N1 influenza vaccine candidate based on Cytos' proprietary bacteriophage Qbeta virus-like particle technology.

17 May 2013

Soligenix starts first clinical study for development of SGX203 for pediatric Crohn's disease

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has initiated the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease.

15 May 2013

Breo Ellipta gets FDA approval for treatment of airflow obstruction in patients with COPD

The U.S. Food and Drug Administration today approved Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema.

13 May 2013

FDA approves Novartis' Ilaris for treatment of active systemic juvenile idiopathic arthritis

Novartis announced that the US Food and Drug Administration has approved Ilaris (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis in patients aged 2 years and older.

10 May 2013

New official clinical practice guidelines on diagnosis, management of EIB

The American Thoracic Society has released new official clinical practice guidelines on the diagnosis and management of exercise-induced bronchoconstriction, the acute airway narrowing that occurs as a result of exercise.

2 May 2013

Specific inflammatory pattern found in patients with pneumonia and COPD

Patients with community-acquired pneumonia on a background of chronic obstructive pulmonary disease have a different early inflammatory pattern than patients with CAP only, a prospective study shows.

30 Apr 2013

Specific inflammatory pattern found in patients with pneumonia and COPD

Patients with community-acquired pneumonia on a background of chronic obstructive pulmonary disease have a different early inflammatory pattern than patients with CAP only, a prospective study shows.

29 Apr 2013

Alimera announces availability of ILUVIEN in U.K. for chronic DME treatment

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that ILUVIEN®, the first sustained release pharmaceutical product for the treatment of chronic diabetic macular edema, is now available in the United Kingdom.

29 Apr 2013

Nanogels to attack lupus: an interview with Dr Look and Dr Fahmy, Yale University

Nanogels are synthetic particles that can be used for drug delivery. They are approximately 100 nm to 200 nm in diameter, and are made from safe, biocompatible materials: a gel-like interior and a lipid exterior.

24 Apr 2013

Rheumatoid arthritis diagnosis: an interview with Dr. Stan Naides, Medical Director, Quest Diagnostics

Rheumatoid arthritis (RA) is an autoimmune disorder that can cause debilitating joint damage. In cases of RA, the immune system attacks the body’s own tissues, especially the membranes that line the joints. As a result, fluid builds up in the joints, causing pain and systemic inflammation, leading to joint destruction if untreated.

From Quest Diagnostics 23 Apr 2013

Study: Use of anti-TNF therapies in RA patients does not increase risk of herpes zoster

Patients with rheumatoid arthritis (RA) who initiated use of anti-tumor necrosis factor therapies were not at a higher risk of developing herpes zoster (shingles), compared with patients who initiated nonbiologic treatment regimens, according to research from the University of Alabama at Birmingham (UAB) and the Oregon Health and Science University. The findings appeared in the March 6, 2013, issue of the Journal of the American Medical Association (JAMA).

22 Apr 2013

FDA's PADAC supports approval of BREO ELLIPTA as once-daily inhaled treatment for COPD

GlaxoSmithKline plc and Theravance, Inc. today announced that the Pulmonary-Allergy Drugs Advisory Committee to the US Food and Drug Administration voted that the efficacy and safety data provide substantial evidence to support approval of BREO ELLIPTA as a once-daily inhaled treatment for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (9 for, 4 against) and also for the reduction of COPD exacerbations in patients with a history of exacerbations (9 for, 4 against).

18 Apr 2013

Carticept Medical gets FDA clearance for Navigator Delivery System

Carticept Medical, Inc., a developer of innovative drug delivery systems, announced today that it has received 510(k) clearance from the Food and Drug Administration for its enhanced Navigator Delivery System, the first and only FDA-cleared, computer-controlled injection system intended to increase the efficiency, comfort, safety and accuracy of musculoskeletal injections.

16 Apr 2013

FDA approves Taro's NDA for Topicort Topical Spray

Taro Pharmaceutical Industries Ltd. reported today that it has received approval from the U.S. Food and Drug Administration for its New Drug Application Topicort (desoximetasone) Topical Spray, 0.25%.

15 Apr 2013

Athletes with vocal cord disorder inappropriately treated for exercise-induced asthma

Athletes with a vocal cord disorder that restricts breathing are more likely to be misdiagnosed and inappropriately treated for exercise-induced asthma, according to research presented today at the Triological Society's 116th Annual Meeting.

15 Apr 2013

Columbia University Medical Center, NewYork-Presbyterian Hospital present research works at AAN meeting

The following research from Columbia University Medical Center and NewYork-Presbyterian Hospital is being presented at the 65th annual meeting of the American Academy of Neurology, March 16-23, 2013, in San Diego.

18 Mar 2013

RA patients who initiate anti-TNF therapies do not have higher risk of shingles: Study

Although patients with rheumatoid arthritis have a disproportionately higher incidence of herpes zoster (shingles), an analysis that included nearly 60,000 patients with RA and other inflammatory diseases found that those who initiated anti-tumor necrosis factor therapies were not at higher risk of herpes zoster compared with patients who initiated nonbiologic treatment regimens, according to a study appearing in the March 6 issue of JAMA.

7 Mar 2013

Corticosteroid News and Research

Study shows 1 in 8 patients at risk of developing serious ADE take OTC NSAIDs

Epidural steroid injection is associated with increased spinal fracture

Prosonix commences Phase 2 clinical study of PSX1002 for treatment of moderate to severe COPD

A*STAR, Cytos Biotechnology provide update on Phase 1 clinical trial of H1N1 influenza vaccine

Soligenix starts first clinical study for development of SGX203 for pediatric Crohn's disease

Breo Ellipta gets FDA approval for treatment of airflow obstruction in patients with COPD

FDA approves Novartis' Ilaris for treatment of active systemic juvenile idiopathic arthritis

New official clinical practice guidelines on diagnosis, management of EIB

Specific inflammatory pattern found in patients with pneumonia and COPD

Specific inflammatory pattern found in patients with pneumonia and COPD

Alimera announces availability of ILUVIEN in U.K. for chronic DME treatment

Nanogels to attack lupus: an interview with Dr Look and Dr Fahmy, Yale University

Rheumatoid arthritis diagnosis: an interview with Dr. Stan Naides, Medical Director, Quest Diagnostics

Study: Use of anti-TNF therapies in RA patients does not increase risk of herpes zoster

FDA's PADAC supports approval of BREO ELLIPTA as once-daily inhaled treatment for COPD

Carticept Medical gets FDA clearance for Navigator Delivery System

FDA approves Taro's NDA for Topicort Topical Spray

Athletes with vocal cord disorder inappropriately treated for exercise-induced asthma

Columbia University Medical Center, NewYork-Presbyterian Hospital present research works at AAN meeting

RA patients who initiate anti-TNF therapies do not have higher risk of shingles: Study

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News